NCT04716998View on ClinicalTrials.gov

Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

MesenCure

Three administrations of MesenCure in addition to standard care

Trial Locations (3)

15208

BARUCH PADEH Medical Center, Poriya, Tiberias

3109601

Rambam Health campus, Haifa

7661041

Kaplan Medical Center, Rehovot

All Listed Sponsors
lead

BonusBio Group Ltd

INDUSTRY

NCT04716998 - Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19 | Biotech Hunter | Biotech Hunter